A Screening Study for the ACH471-100 Treatment Study in Patients with Untreated Paroxysmal Nocturnal Hemoglobinuria
Phase of Trial: Phase I
Latest Information Update: 07 Jul 2017
At a glance
- Drugs ACH 4471 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 07 Jul 2017 Status changed from recruiting to completed.
- 23 Feb 2017 Status changed from not yet recruiting to recruiting.
- 11 Jan 2017 New trial record